Advertisement

Topics

Companies Related to "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" [Most Relevant Company Matches] - Page: 5 RSS

19:17 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Immune Tumor Response Multi component Immune Based" Companies 101–125 of 8,100+

Relevant

Celldex therapeutics

Celldex is a biotechnology company focused on the discovery, development and commercialization of novel immunotherapeutics including human monoclonal antibodies for the treatment of cancer, infectious diseases, and immune system disorders. We are advancing a pipeline of clinical and pre-clinical product candidates.Our proprietary core technology utilizes human monoclonal antibodies to directly tar...


Deciphera Pharmaceuticals, Inc.,

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known t...

TNI BioTech, Inc.

TNI BioTech, Inc. is a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, ch...


Novis Pharmaceuticals

Novis Pharmaceuticals is a leading national distributor of some of the world's leading plasma-derived products such as albumin, immune globulin, hyperimmunes and anti-hemophilic Factors VII, VIII and IX. Hospitals, home infusion therapy companies and other healthcare providers use these biotherapeutics to treat trauma, autoimmune conditions, immune deficiencies, infectious diseases, bleeding ...

Active Biotech Research AB

Active Biotech focuses on developing pharmaceuticals for medical fields in which the immune system plays a central role.Our pharmaceutical development is based on our specialist know-how in the field of immunology. We possess a unique infrastructure that includes highly experienced researchers who combine cutting edge expertise with efficient project work focusing on clearly defined targets. Our p...

Batu Biologics

Founded in 2013, Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area of immune modulation. The company’s products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its tw...

Viventia Biotech Inc.

Viventia Biotech Inc. is a leader in developing innovative therapeutics based upon the human immune response to cancer. Through its Hybridomics™ discovery platform and ImmunoMine™ screening technology, the Company is focused on developing "Totally Human" monoclonal antibodies either as targeted therapeutics, Armed Antibodies™, or as direct treatments to fight multiple forms of cancer.

Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known t...

CytoReason

Born out of 10 years’ research from Stanford and the Technion, CytoReason is the only AI company to focus entirely on the immune system in developing its proprietary data and AI / machine-learning approach. This approach is capable of constructing 3-dimensional maps of previously hidden, immune-system relationships at a cellular, tissue and disease le...

Beardsworth

Beardsworth is a full-service CRO. We specialize in complicated trials in difficult therapeutic areas. We are an oncology niche provider. Beardsworth has recently conducted 50 oncology and oncology-related clinical trials. While we specialize in oncology, we have broad-based experience in other therapeutic areas, including endocrinology, cardiovascular, immune response systems, dermatology and i...

Immune Network Research Limited

Profile:A Vancouver, BC - based company, Immune Network Research Ltd. identifies outstanding commercial opportunities for new drug treatments, and takes them closer to market through rapid completion of critical milestones. Completion of these milestones is followed by licensing, alliances or spin-offs in order to create maximum return on investment for our shareholders.Strategy:Immune Network Res...

Enumeral Biomedical Holdings, Inc.

Enumeral Biomedical is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. We have a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation. Our unique capabilities enable us to measure drug effects in a patient-specific manner, providing th...

GoodBelly Probiotic Fruit Drink

Made with the well-researched probiotic strain, Lactobacillus plantarum 299v (LP299V®), GoodBelly supports digestive health when consumed daily. Unlike many other live and active cultures, LP299Vsurvives passage beyond the stomach’s acidic environment in order to support the rest of the digestive system, and ultimately overall health.* GoodBelly of...

AbCellera Biologics, Inc.

AbCellera is a privately held company that develops next-generation monoclonal antibody therapies and provides enabling technologies to biotechnology and pharmaceutical partners. AbCellera’s lead technology is a proprietary single-cell antibody discovery and immune profiling platform that allows for high-throughput screening of natural immune repertoi...

CBT Pharmaceuticals

CBT Pharmaceuticals is a life sciences company developing innovative oncology therapeutics targeting the growth and proliferation of cancer cells. The company is advancing a pipeline of four development-stage assets including CBT-101, an oral c-Met inhibitor targeting the epithelial-mesenchymal transition (EMT) pathway in cancers and CBT-501, a novel human...

Isarna Therapeutics GmbH

Isarna Therapeutics has an unmatched commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. Isarna Therapeutics are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.  The role of tgf-beta in cancer The cytokine human transforming growth ...

Biological Mimetics, Inc.,

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of pu...

MabVax Therapeutics, Inc.

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. The company was formed to exploit key aspects of the work of Dr. Philip Livingston and colleagues at MSKCC who have developed cancer vaccines against gangliosides and other carbohydrate antigens that...

ALX Oncology

ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein comprised of an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobuli...

Entelos Incorporated

Developing computer models of human physiology that simulate health, disease, and response to potential treatments, Entelos is bringing insight to the life sciences through technology.Currently focusing on metabolism and immune diseases, Entelos markets PhysioLabs for asthma and obesity. Models for HIV-AIDS, adipocyte, and diabetes are in development and will be released soon.

Alexo Therapeutics

Alexo Therapeutics is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin....

PsiOxus Therapeutics Ltd.

PsiOxus Therapeutics is an Oxford, UK-based development stage biotechnology company with a particular focus on immune therapeutics in oncology. PsiOxus has developed a patented platform for tumour-targeted delivery based on its oncolytic vaccine, enadenotucirev. Enadenotucirev’s unique design allows it to be delivered systemically via intravenous ...

Tamarack Biotics

Founded in 2011, Tamarack Biotics produces TruActive™, a range of dairy-based protein ingredients ideal for sports bars, powdered nutrition and powder supplements. Derived from patented UV treatment and low-temperature technologies that achieve the same safety standards as traditionally pasteurized products, TruActive retains more immune active protei...

GeneCentric Therapeutics, Inc.

GeneCentric Therapeutics, Inc., based in Research Triangle Park, N.C., is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our initial approach applies our Cancer Subtype Platform (CSP®) to parse the complexity of tumor biology and generate geno...

Probiodrug AG

Probiodrug AG was established in 1997 as a spin off of the "Hans-Knöll-Institut für Wirkstoffforschung". Probiodrug is a wholly privately owned science driven drug development company, founded by Dr.'s. Hans-Ulrich Demuth and Konrad Glund, biochemists by education. The company is financed through venture capital and silent partnerships and successfully acquired R&D grants. The scientific advisor...


More From BioPortfolio on "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks